Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 6/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.53 |
| ▸ | GAA | P10253 | 5/20 | 0.53 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.53 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.53 |
| ▸ | GSK3A | P49840 | 1/20 | 0.53 |
| ▸ | GSK3B | P49841 | 1/20 | 0.53 |
| ▸ | GFER | P55789 | 1/20 | 0.53 |
| ▸ | BRD4 | O60885 | 2/20 | 0.52 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.49 |
| ▸ | FBP1 | P09467 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.46 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5152605 | 0.95 | MEN1 (0.51) | MEN1KMT2AGAACDK5CDK5R1 | |
| SCHEMBL3950737 | 0.90 | MEN1 (0.58) | MEN1KMT2AGAACDK5CDK5R1 | |
| SCHEMBL4931881 | 0.89 | HIF1A (0.51) | MEN1KMT2AGAACDK5CDK5R1 | |
| SCHEMBL3945167 | 0.89 | BRD4 (0.61) | MEN1KMT2AGFERBRD4SERPINE1 | |
| SCHEMBL3945225 | 0.88 | BRD4 (0.54) | MEN1KMT2AGAAGFERBRD4 | |
| SCHEMBL4934791 | 0.88 | UQCRB (0.57) | MEN1KMT2AGAACDK5CDK5R1 | |
| SCHEMBL3950699 | 0.88 | BRD4 (0.50) | MEN1KMT2AGAACDK5CDK5R1 | |
| SCHEMBL3949320 | 0.88 | CA1 (0.48) | MEN1KMT2AGAACDK5CDK5R1 | |
| SCHEMBL3944980 | 0.88 | BRD4 (0.53) | MEN1KMT2AGAAGFERBRD4 | |
| SCHEMBL3950142 | 0.88 | BRD4 (0.53) | MEN1KMT2ABRD4SERPINE1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1802572-B1 | INDOL DERIVATIVES AS INHIBITORS OF SOLUBLE ADENYLYL CYCLASE | BAYER SCHERING PHARMA AG (DE) | 2009-04-22 | — | — | EP | disclosed |
| US-20080004268-A1 | INHIBITORS OF SOLUBLE ADENYLATE CYCLASE | NGUYEN DUY | 2008-01-03 | — | — | US | disclosed |
| EP-1802572-A1 | INDOL DERIVATIVES AS INHIBITORS OF SOLUBLE ADENYLYL CYCLASE | Bayer Schering Pharma Aktiengesellschaft (DE) | 2007-07-04 | — | — | EP | disclosed |
| US-20060074084-A1 | Inhibitors of soluble adenylate cyclase | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-04-06 | — | — | US | disclosed |
| WO-2006032541-A1 | INDOL DERIVATIVES AS INHIBITORS OF SOLUBLE ADENYLYL CYCLASE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004268-A1 | INHIBITORS OF SOLUBLE ADENYLATE CYCLASE | ADCY1, ADCY2, ADCY5 | MEN1 712/4885KMT2A 4518/4885GAA 791/4885 |
| US-20060074084-A1 | Inhibitors of soluble adenylate cyclase | ADCY1, ADCY2, ADCY5 | MEN1 712/4885KMT2A 4518/4885GAA 791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.